Biopure analysis
BIOPURE CORP.
I. Summary
It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood in th....
Biopure Company - Launching of Oxyblobin
Executive Summary
Biopure is a small and private developer of human (Hemopure) and animal (Oxyglobin) blood substitutes. Biopure is faced with the decision of whether to immediately launch Oxyglobin (Og) or wait until after the launch of hemapure (Hp), which will be in about two years following FDA....
Biopure Corporation: Oxyglobin Analysis
In order to maximize Biopures potential in the blood substitutes market, Biopure should release Oxyglobin in the veterinary market now, and leverage the benefits derived from Oxyglobin as a springboard to release the potentially more profitable Hemopure. Correctly implementing the relea....
Case Study: Biopure Corporation
Situation analysis
External analysis
In the 1998 the world of medicine is on the verge of revolution in the blood transfusion market. Three companies, namely Biopure, Baxter and Northfield, are in the final stages of the approval of human blood substitutes for commercial release. Furthermore, Bio....
PRIVACY
|
TERMS & CONDITIONS
|
MEMBER LOGIN
|
CUSTOMER SUPPORT
